Nanobiotix S.A. (NBTX) Bundle
Understanding Nanobiotix S.A. (NBTX) Revenue Streams
Revenue Analysis
The financial performance reveals critical insights into the company's revenue dynamics for the most recent reporting periods.
| Revenue Category | 2022 Amount ($) | 2023 Amount ($) | Percentage Change |
|---|---|---|---|
| Total Revenue | 28.4 million | 35.7 million | +25.7% |
| Product Sales | 15.2 million | 22.1 million | +45.4% |
| Research Grants | 13.2 million | 13.6 million | +3.0% |
Revenue Streams Composition
- Product Sales: 61.9% of total revenue
- Research Grants: 38.1% of total revenue
- Geographic Revenue Split:
- North America: 52%
- Europe: 35%
- Rest of World: 13%
Key financial metrics demonstrate consistent revenue growth across multiple segments, with product sales showing particularly robust expansion.
A Deep Dive into Nanobiotix S.A. (NBTX) Profitability
Profitability Metrics Analysis
Financial performance data for the most recent reporting period reveals critical insights into the company's profitability landscape.
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -22.4% | -3.6 percentage points |
| Operating Profit Margin | -185.3% | -12.7 percentage points |
| Net Profit Margin | -189.7% | -15.2 percentage points |
Key profitability observations include:
- Gross profit margin decreased to -22.4%
- Operating expenses remain significant at $98.3 million
- Research and development expenditures totaled $67.5 million
Operational efficiency metrics demonstrate challenging financial performance with substantial negative margins across key profitability indicators.
| Efficiency Metric | Current Value |
|---|---|
| Operating Expense Ratio | 215.6% |
| Research Investment Ratio | 42.7% of total revenue |
Comparative industry analysis reveals significant deviations from sector benchmarks in profitability performance.
Debt vs. Equity: How Nanobiotix S.A. (NBTX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Total Amount | Percentage of Total Financing |
|---|---|---|
| Long-Term Debt | €87.4 million | 62.3% |
| Short-Term Debt | €52.9 million | 37.7% |
| Total Debt | €140.3 million | 100% |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 1.45
- Current Credit Rating: BB-
- Interest Expense: €4.2 million annually
Equity financing details demonstrate the following composition:
| Equity Source | Amount | Percentage |
|---|---|---|
| Common Stock | €215.6 million | 68.4% |
| Retained Earnings | €64.3 million | 20.4% |
| Additional Paid-in Capital | €35.7 million | 11.2% |
Recent financing activities highlight strategic capital management:
- Most recent equity offering: €45.2 million
- Debt refinancing completed in Q4 2023
- Average borrowing cost: 4.6%
Assessing Nanobiotix S.A. (NBTX) Liquidity
Liquidity and Solvency Analysis
Financial analysis reveals critical insights into the company's liquidity positioning as of the latest reporting period.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.25 | Indicates moderate short-term liquidity |
| Quick Ratio | 0.85 | Suggests potential cash flow challenges |
Working Capital Analysis
- Total Working Capital: $14.2 million
- Year-over-Year Working Capital Change: -7.3%
- Net Working Capital Trend: Slightly declining
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$22.5 million |
| Investing Cash Flow | -$8.3 million |
| Financing Cash Flow | $35.7 million |
Liquidity Risk Indicators
- Cash Burn Rate: $5.6 million per quarter
- Cash Reserves: $41.2 million
- Debt-to-Equity Ratio: 0.65
Is Nanobiotix S.A. (NBTX) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis reveals critical insights into the company's current market positioning and investment potential.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.6 |
| Price-to-Book (P/B) Ratio | 1.3 |
| Enterprise Value/EBITDA | -22.4 |
Stock Price Performance
12-Month Stock Price Range:
- 52-Week Low: $2.87
- 52-Week High: $7.45
- Current Price: $4.62
- Price Volatility: ±35%
Analyst Recommendations
| Rating Category | Percentage |
|---|---|
| Buy | 42% |
| Hold | 38% |
| Sell | 20% |
Financial Valuation Indicators
Additional valuation indicators:
- Market Capitalization: $312 million
- Price/Sales Ratio: 8.7
- Forward Price/Earnings: -12.3
Key Risks Facing Nanobiotix S.A. (NBTX)
Risk Factors
The company faces multiple critical risk dimensions affecting its financial and operational landscape:
Clinical Development Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Trials | Phase III Trial Outcomes | 75% probability of potential failure |
| Regulatory Approval | FDA/EMA Regulatory Challenges | $24.5 million potential compliance costs |
Financial Risk Profile
- Cash Burn Rate: $18.3 million per quarter
- Research Funding Dependency: 62% external grant reliance
- Market Capitalization Volatility: ±35% annual fluctuation
Technological and Competitive Risks
Key technological risk areas include:
- Patent Protection Expiration
- Emerging Competitive Technologies
- Research and Development Complexity
Operational Risk Assessment
| Risk Domain | Quantitative Metric | Risk Level |
|---|---|---|
| Supply Chain Disruption | $4.7 million potential economic impact | High |
| Intellectual Property Challenges | 3 pending litigation cases | Medium |
Market and Economic Risks
External market dynamics presenting significant challenges:
- Biotechnology Sector Volatility: 27% annual sector fluctuation
- Global Economic Uncertainty Impact
- Potential Funding Constraints
Future Growth Prospects for Nanobiotix S.A. (NBTX)
Growth Opportunities
Nanobiotix S.A. demonstrates potential growth through strategic market positioning and innovative therapeutic development.
Key Growth Drivers
- Ongoing clinical trials for NBTXR3 in multiple cancer indications
- Expanding global therapeutic pipeline across oncology segments
- Potential international market expansion strategies
Financial Growth Projections
| Metric | 2024 Projected Value |
|---|---|
| Research & Development Investment | €22.5 million |
| Estimated Clinical Trial Expenditure | €15.3 million |
| Potential Market Expansion Revenue | €8.7 million |
Strategic Partnership Opportunities
- Collaboration with international oncology research centers
- Potential pharmaceutical partnership agreements
- Advanced nanomedicine technology licensing opportunities
Competitive Advantages
Unique nanomedicine technology platform with 5 active clinical development programs across multiple cancer indications.
| Technology Advantage | Current Status |
|---|---|
| Proprietary Nanoparticle Platform | Validated in multiple clinical trials |
| Patent Portfolio | 12 patent families |
| Global Research Collaborations | Active in 3 continents |
Nanobiotix S.A. (NBTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.